Silvia Novello, MD, PhD, of the University of Turin, discusses a much-neglected aspect of lung cancer: It is not just the province of men; women are affected in great numbers as well.
Alice T. Shaw, MD, PhD, of Massachusetts General Hospital, summarizes efficacy and safety data from studies on crizotinib, brigatinib, and alectinib for ALK-positive non–small cell lung cancer (ORAL 33.03, 33.06, 33.07).
Everett E. Vokes, MD, of the University of Chicago, summarizes expert views on treating stage IIIA disease: decision-making in selecting patients for surgery; multiple-modality choices; and using induction chemotherapy (Abstract ED10).
Philip Bonomi, MD, of Rush Medical College, summarizes the findings on anamorelin and its use in advanced NSCLC for improvement in anorexia/cachexia symptoms (Abstracts ORAL 29.01, ORAL 29.02).
Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, summarizes a workshop he conducted on the state of the art in next-generation sequencing of lung cancer (Abstract WS 01.07).
James L. Mulshine, MD, of Rush University Medical Center, discusses the profound challenges of implementing national CT screening to ensure delivery of high-quality, best-practice early lung cancer detection in the target population of tobacco-exposed individuals (Abstract MS 15.01).
